In this issue of Blood, Locatelli et al compare the results of histocompatible family donor bone marrow and cord blood transplants (BMT and CBT) for severe β thalassemia (SBT) and sickle cell disease (SCD) as experienced by the Eurocord and European Blood and Marrow Transplantation group and collaborating centers in the United States, Hong Kong, and Israel between 1994 and 2005.1 Obviously, many changes in medical care and particularly MHC typing occurred over that decade, so this retrospective represents a moving target, but some firm points can be made for which we are indebted to this excellent group. © 2013 by The American Society of Hematology.
CITATION STYLE
Nathan, D. G. (2013, August 8). Hemoglobin disorders: A look to the future. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2013-06-506154
Mendeley helps you to discover research relevant for your work.